Overview
SER market data
Price History
SER price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.88 Diluted earnings per share over the trailing twelve months.
- Beta
- 7.74 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.22 – $7.92 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $31.7 · P/B 69.50 · P/S 220.17.
Company News
8-K filing — Serina Therapeutics, Inc. (SER)SEC EDGAR · Jul 23, 2026, 8:51 PM
Serina Therapeutics Completes Enrollment And Dosing In Cohort 1 Of Ongoing Phase 1b Registrational Clinical Trial Evaluating SER-252 In Patients With Advanced Parkinson’s DiseaseBenzinga · Jul 23, 2026, 10:10 AM
Serina Therapeutics Completes Sentinel Dosing In Group 1 Of Its Phase 1b Study Of SER-252 To Treat Parkinson's DiseaseBenzinga · Jul 9, 2026, 3:50 PM
BTIG Initiates Coverage On Serina Therapeutics with Buy Rating, Announces Price Target of $8Benzinga · Jul 1, 2026, 12:00 PM
Gannet BioChem To Support Development Activities For SER-252, Serina Therapeutics' Investigational Therapy For Advanced Parkinson's DiseaseBenzinga · Jun 30, 2026, 1:10 PM
Serina Therapeutics Files Prospectus For Offering 16.45M Common Shares On Behalf Of Selling StockholdersBenzinga · May 22, 2026, 8:10 PM
Serina Therapeutics Says Phase 1b Registrational Clinical Study of SER-252 Underway In Advanced Parkinson's Disease; TFL Data From The SAD Study Arm Targeted For First Half of 2027Benzinga · May 14, 2026, 9:53 PM
Serina Therapeutics Q1 EPS $(0.58) Misses $(0.44) EstimateBenzinga · May 14, 2026, 8:43 PM